Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure.

COVID-19 ELISA IgG SARS-CoV-2 dried blood spots essential worker nucleocapsid receptor binding domain serological testing

Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
16 Mar 2021
Historique:
pubmed: 26 11 2020
medline: 26 11 2020
entrez: 25 11 2020
Statut: epublish

Résumé

Estimates of seroprevalence to SARS-CoV-2 vary widely and may influence vaccination response. We ascertained IgG levels across a single US metropolitan site, Chicago, from June 2020 through December 2020. Participants (n=7935) were recruited through electronic advertising and received materials for a self-sampled dried blood spot assay through the mail or a minimal contact in person method. IgG to the receptor binding domain of SARS-CoV-2 was measured using an established highly sensitive and highly specific assay. Overall seroprevalence was 17.9%, with no significant difference between method of contact. Only 2.5% of participants reported having had a diagnosis of COVID-19 based on virus detection, consistent with a 7-fold greater exposure to SARS-CoV-2 measured by serology than detected by viral testing. The range of IgG level observed in seropositive participants from this community survey overlapped with the range of IgG levels associated with COVID-19 cases having a documented positive PCR positive test. From a subset of those who participated in repeat testing, half of seropositive individuals retained detectable antibodies for 3-4 months. Quantitative IgG measurements with a highly specific and sensitive assay indicate more widespread exposure to SARS-CoV-2 than observed by viral testing. The range of IgG concentration produced from these asymptomatic exposures is similar to IgG levels occurring after documented non-hospitalized COVID-19, which is considerably lower than that produced from hospitalized COVID-19 cases. The differing ranges of IgG response, coupled with the rate of decay of antibodies, may influence response to subsequent viral exposure and vaccine.

Sections du résumé

Background UNASSIGNED
Estimates of seroprevalence to SARS-CoV-2 vary widely and may influence vaccination response. We ascertained IgG levels across a single US metropolitan site, Chicago, from June 2020 through December 2020.
Methods UNASSIGNED
Participants (n=7935) were recruited through electronic advertising and received materials for a self-sampled dried blood spot assay through the mail or a minimal contact in person method. IgG to the receptor binding domain of SARS-CoV-2 was measured using an established highly sensitive and highly specific assay.
Results UNASSIGNED
Overall seroprevalence was 17.9%, with no significant difference between method of contact. Only 2.5% of participants reported having had a diagnosis of COVID-19 based on virus detection, consistent with a 7-fold greater exposure to SARS-CoV-2 measured by serology than detected by viral testing. The range of IgG level observed in seropositive participants from this community survey overlapped with the range of IgG levels associated with COVID-19 cases having a documented positive PCR positive test. From a subset of those who participated in repeat testing, half of seropositive individuals retained detectable antibodies for 3-4 months.
Conclusions UNASSIGNED
Quantitative IgG measurements with a highly specific and sensitive assay indicate more widespread exposure to SARS-CoV-2 than observed by viral testing. The range of IgG concentration produced from these asymptomatic exposures is similar to IgG levels occurring after documented non-hospitalized COVID-19, which is considerably lower than that produced from hospitalized COVID-19 cases. The differing ranges of IgG response, coupled with the rate of decay of antibodies, may influence response to subsequent viral exposure and vaccine.

Identifiants

pubmed: 33236031
doi: 10.1101/2020.11.17.20233452
pmc: PMC7685344
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA060553
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002389
Pays : United States

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

Conflicts of Interest: Thomas McDade has a financial interest in EnMed Microanalytics, a company that specializes in laboratory testing of dried blood spot samples. All other authors declare no conflicts of interest.

Auteurs

Alexis R Demonbreun (AR)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Department of Pharmacology, Northwestern University Feinberg School of Medicine.

Thomas W McDade (TW)

Department of Anthropology and Institute for Policy Research, Northwestern University.

Lorenzo Pesce (L)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Department of Pharmacology, Northwestern University Feinberg School of Medicine.

Lauren A Vaught (LA)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine.

Nina L Reiser (NL)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine.

Elena Bogdanovic (E)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine.

Matthew P Velez (MP)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine.

Ryan R Hsieh (RR)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine.

Lacy M Simons (LM)

Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine.

Rana Saber (R)

Institute for Sexual and Gender Minority Health and Wellbeing and Department of Medical Social Sciences, Northwestern University.

Daniel T Ryan (DT)

Institute for Sexual and Gender Minority Health and Wellbeing and Department of Medical Social Sciences, Northwestern University.

Michael G Ison (MG)

Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine.
Division of Organ Transplantation, Dept. of Surgery, Northwestern University Feinberg School of Medicine.

Judd F Hultquist (JF)

Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine.

John T Wilkins (JT)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine.

Richard T D'Aquila (RT)

Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine.

Brian Mustanski (B)

Institute for Sexual and Gender Minority Health and Wellbeing and Department of Medical Social Sciences, Northwestern University.

Elizabeth M McNally (EM)

Center for Genetic Medicine, Northwestern University Feinberg School of Medicine.
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine.
Department of Biochemistry and Molecular Genetics, Northwestern University.

Classifications MeSH